PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1555497
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1555497
Oral Solid Dosage Contract Manufacturing Market size was valued at USD 35,897.18 Million in 2023, expanding at a CAGR of 5.6% from 2024 to 2032.
Oral Solid Dosage (OSD) Contract Manufacturing is the process where pharmaceutical companies outsource the production of solid dosage forms, like tablets, capsules, and powders, to specialized third-party manufacturers. These contract manufacturers handle various stages of production, from formulation development to packaging, ensuring that the products meet required quality and regulatory standards.
Oral Solid Dosage Contract Manufacturing Market- Market Dynamics
Growing demand for generic drugs and high demand from biotech industries are expected to propel market demand
The increasing adoption of generic drugs, due to their cost-effectiveness compared to branded medications, drives demand for OSD contract manufacturing services. Generic drug manufacturers often rely on contract manufacturers to produce high-quality, cost-effective tablets and capsules. Contract manufacturing offers cost advantages by reducing the need for capital investment in manufacturing facilities and equipment. This scalability is attractive to companies looking to adjust production volumes based on market demand without significant upfront investment.
The expansion of pharmaceutical and biotech companies, especially those focused on new drug development, leads to the need for contract manufacturing services. These companies often lack the resources or facilities to handle large-scale production in-house. In addition, growing pharmaceutical markets in regions such as Asia-Pacific and Latin America create new opportunities for contract manufacturing. Pharmaceutical companies seeking to enter these emerging markets often partner with local contract manufacturers to navigate regulatory requirements and distribution network capabilities.
Oral Solid Dosage Contract Manufacturing Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.6% over the forecast period (2024-2032)
Based on Product Type segmentation, the tablets segment was predicted to show maximum market share in the year 2023, owing to their high cost-effectiveness.
Based on Application segmentation, the drug product development segment was the leading application in 2023, owing to high demand from novel drug developments.
Based on End User segmentation, the large companies' segment was the leading End User in 2023, owing to high demand for solid dose formulations & manufacturing.
Based on region, Asia Pacific was the leading revenue generator in 2023, due to the growing production in API industries.
The Global Oral Solid Dosage Contract Manufacturing Market is segmented based on Product Type, Application, End User, and Region.
The market is divided into three categories based on Product Type: tablets, capsules, powder, granules, and others. The tablet segment dominates the market. Easy formulation and fast production are increasing the segment growth. The capsules segment is expected to grow at the fastest rate over the forecast period.
The market is divided into four categories based on Application: drug product development, fill finish product manufacturing, API manufacturing, and others. The drug product development segment dominates the market. Supportive government initiatives for novel drug discoveries are boosting segment growth.
The market is divided into three categories based on End Users: large companies, small & medium sized companies, and others. The large companies segment dominates the market and is expected to maintain its high dominance during the forecast period. Contract manufacturing organizations and product innovations are contributing to segment demand.
Oral Solid Dosage Contract Manufacturing Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America has the presence of many pharmaceutical and biotech companies, along with a strong emphasis on R&D and innovation, which drives demand. The region also benefits from advanced manufacturing technologies and a well-established regulatory framework. Asia Pacific dominates the global market. Lower production costs, a growing pharmaceutical industry, and increasing investment in healthcare drive market growth.
The Oral Solid Dosage (OSD) Contract Manufacturing market is competitive, with numerous players offering a range of contract manufacturing services and innovations. Companies are investing significantly in advanced manufacturing technologies, such as continuous manufacturing and high-speed compression, to improve efficiency, reduce costs, and enhance product quality. Key players are expanding their manufacturing facilities and capabilities to meet the growing demand for OSD products and to accommodate new product launches.
In July 2023, Aenova Group and Galvita formed a strategic partnership to enhance oral dosage forms' formulation, development, and production.
In April 2023, Aenova invested around USD 22 million to expand its high-volume solids site in Tittmoning, U.S., resulting in increased capacity.
In March 2023, Lonza completed the construction of clinical & drug product manufacturing in Visp, Switzerland.